CytomX Therapeutics (CTMX) to Release Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.16) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $25.12 million during the quarter, compared to analyst estimates of $21.79 million. CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. During the same period last year, the business earned ($0.02) EPS. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Trading Down 1.0 %

NASDAQ:CTMX traded down $0.01 during mid-day trading on Tuesday, hitting $1.00. The stock had a trading volume of 563,313 shares, compared to its average volume of 2,572,858. The stock has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $1.49. The company has a market capitalization of $78.12 million, a PE ratio of 7.14 and a beta of 1.06. CytomX Therapeutics has a twelve month low of $0.99 and a twelve month high of $5.85.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, September 13th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.77.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.